Brief: Daewoong Pharmaceutical Announces Successful Phase 3 Results For New Antidiabetic Drug's Triple Combination Therapy
25/02/2022 14:11
Feb 25 (Reuters) - Daewoong Pharma 069620.KS :
* DAEWOONG PHARMACEUTICAL ANNOUNCES SUCCESSFUL PHASE 3
TOPLINE
RESULTS FOR NEW ANTIDIABETIC DRUG'S TRIPLE COMBINATION THERAPY
* DAEWOONG PHARMA - CONFIRMED POSITIVE PHASE 3 TOPLINE
RESULTS IN
ADDITION TO ENAVOGLIFLOZIN MONOTHERAPY AND METFORMIN COMBINATION
THERAPY
Source text for Eikon: ID:nPnbb6cRca
Further company coverage: 069620.KS
((reuters.briefs@thomsonreuters.com;))
Recent news on Daewoong Pharma
See all newsBrief: Daewoong Pharma Q2 Operating. Profit 77 Billion Won, Up 23% Y/Y
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier